House mark for pharmaceutical and biopharmaceutical products for the treatment of cancer, MDS, genetic disorders and immunological disorders; novel protein drugs for use in the area of oncology, immune therapies and for the treatment of metabolic disorders

'area':26 'biopharmaceut':6 'cancer':12 'disord':15,18,37 'drug':21 'genet':14 'hous':1 'immun':29 'immunolog':17 'mark':2 'mds':13 'metabol':36 'novel':19 'oncolog':28 'pharmaceut':4 'product':7 'protein':20 'therapi':30 'treatment':10,34 'use':23

House mark for scientific research and development in the area of pharmacy, medicine, biology and genetics, developing treatments for serious and life-threatening diseases as well as broad technology platforms that will lead to new therapies

'area':10 'biolog':14 'broad':29 'develop':7,17 'diseas':25 'genet':16 'hous':1 'lead':34 'life':23 'life-threaten':22 'mark':2 'medicin':13 'new':36 'pharmaci':12 'platform':31 'research':5 'scientif':4 'serious':20 'technolog':30 'therapi':37 'threaten':24 'treatment':18 'well':27

EMD LEXIGEN

Owners

Goods & Services